Trial
NCT03232892
Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of California, San Francisco
Collaborators
Novartis Pharmaceuticals; American Cancer Society, Inc.
Condition
Non-small Cell Lung Cancer
Intervention
Trametinib
Why stopped
Low Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-03